ArticleOral diseases2025
Deciphering Disulfidptosis-Linked lncRNA Patterns as Potential HNSCC Biomarkers.
Article in Oral diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic, Prognostic, and Predictive Molecular Biomarkers in Head and Neck Squamous Cell Carcinoma: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Aberrant DNA hypermethylation-regulated long non-coding RNA RYR3-DT affects ferroptosis and progression of glioma cell through the CoQ10/FSP1 axis.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur investigation sought to uncover the intrinsic features of Head and Neck Squamous Cell Carcinoma (HNSCC), particularly the role of long non-coding RNAs implicated in disulfidptosis (DRLs). MATERIALS AND
methodsWe carried out lncRNA-mRNA RNA-Seq studies on HNSCC cells and harnessed the data from The Cancer Genome Atlas (TCGA), which includes 522 HNSCC tumors and 44 normal specimens. Bioinformatics evaluations aided in recognizing DRLs and estimating their prognostic value. Furthermore, we built a predictive model related to the chosen DRLs to scrutinize its linkage with the patients' prognosis. We also dug into tumor mutation loads and responses to chemotherapy.
resultsOur study identified three key DRLs (LINC02434, AC245041.2, and LINC02762) with considerable correlation to HNSCC prognosis. The risk model, utilizing these DRLs, successfully categorized patients into high-risk and low-risk clusters, uncovering differential survival trajectories. Moreover, the same risk model conveyed unique prognostic potential in HNSCC. Surveying the tumor microenvironment unfolded disparities between the groups, hinting toward potential implications for tactics in immunotherapy. We recognized distinct chemotherapeutic drugs with fluctuating responses across the risk clusters and molecular categories.
conclusionThis investigation not only sheds light on prospective therapeutic pathways but also enhances our grasp of the molecular intricacies of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.